Authors: Kuhn L, Wang C, Tsai WY, Wright TC, Denny L
BACKGROUND:: Cervical cancer prevention should be provided as part of primary healthcare services for HIV-infected women but conventional screening programs are difficult to implement in low-resource settings.
Obstetrics & Gynecology:
July 2010 – Volume 116 – Issue 1 – pp 76-84
Castle, Philip E. PhD, MPH; Fetterman, Barbara SCT (ASCP); Thomas Cox, J.; Shaber, Ruth MD; Poitras, Nancy ACS, PMP; Lorey, Thomas MD; Kinney, Walter MD
BACKGROUND: To estimate the relationship of human papillomavirus (HPV) detection and abnormal cytology with histologic diagnoses of cervical precancer and cancer.
Authors: Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK
OBJECTIVE: Testing for human papillomavirus (HPV) 16 and 18 genotypes, which are known to cause approximately 65-70% of invasive cervical cancer cases, may allow clinicians to identify women at highest risk for underlying cervical intraepithelial neoplasia missed by Pap cytology.
Mark Schiffman, MD, MPH, and Nicolas Wentzensen, MD, PhD
Cervical cancer is one of the most common female
malignancies worldwide; 80% of cases occur in
low-resource regions.1,2 Screening programs have been
very successful in the United States, Europe, and other
regions able to achieve broad and sustained coverage. In
the United States, the disease is controlled at an annual
cost of billions of dollars representing a major commitment
by patients and clinicians.